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Abstract 
Background: Sensitization to ash pollen is underestimated in various regions. The prevalence in Germany is about 
10%. However, allergy to ash pollen is widely overlooked by allergists, since the pollination period of ash and birch in 
central Europe closely overlap and rhinoconjunctival symptoms during April/May are often assigned to birch pol‑
len. Component resolved analysis of the different ash allergens is not routinely available. Therefore, we would like to 
question the usefulness of component resolved diagnostic via olive components, as ash and olive are both part of the 
Oleaceae family.
Methods: 113 patients with nasal provocation and skin prick test to ash were retrospectively compared regarding 
their specific immunoglobulin E antibody profiles with response to native ash extract, rOle e 1, nOle e 7 and rOle e 9.
Results: In nasal provocation testing 58% of 113 patients sensitized to ash were allergic, 42% were only sensitized 
without showing symptoms. Skin prick testing and serology against native ash extract detected most patients sensi‑
tized to ash pollen, whereas rOle e 1 was less sensitive. However, the value of measurements of skin prick test, serol‑
ogy to native ash extract and rOle e 1 did not allow a differentiation between an allergy and clinically silent sensitiza‑
tion. Specific antibodies to nOle e 7 and rOle e 9 were only seen in individual patients and were all positive for native 
ash extract and rOle e 1.
Conclusion: Skin prick testing and serology to native extract of ash pollen are the most reliable tools to diagnose a 
sensitization to ash pollen for patients living in Germany. Component resolved diagnostic to the major allergen rOle e 
1 as representative of the Oleaceae family is possible but was less sensitive. Diagnostic of nOle e 7 and rOle e 9 did not 
show any additional benefit. Regarding differentiation between allergy and clinically silent sensitization to ash pollen, 
provocation is the leading diagnostic tool. Concluding, in routine clinical practice the standard methods—skin prick 
test, serology to native ash extract and provocation testing—remain crucial in the diagnosis and differentiation of ash 
sensitization and allergy.
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Background
Prevalences of allergic disease are increasing. Next to 
grass and herb pollen, also tree pollen are a major source 
of pollinosis, primarily birch-like plants. The prevalence 
of sensitization to birch pollen is 17.4% in the German 
adult population [1]. Therefore, this allergen accounts for 
various rhinoconjunctival symptoms during its season in 
April and May. However, sensitization to European ash 
pollen is widely underestimated in Germany as a reason 
for pollinosis during this time [2]. Since the pollination 
periods of ash and birch strongly overlap, sensitization 
to ash pollen should also be considered being the source 
of allergic symptoms during spring. Sensitization to ash 
pollen is determined as 9.4% in the German adult pop-
ulation [1]. In Italy and France, 18–34% of allergies are 
caused by ash pollen [2, 3].
The European ash tree (Fraxinus excelsior) is found 
in Germany and many other European countries except 
northern Scandinavia and the southern Mediterranean 
[4] and belongs to the Oleaceae family. Moreover, the 
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olive tree (Olea europaea) is one of the major repre-
sentatives of the Oleaceae family [5] and in Europe is 
mainly found in the Mediterranean regions and in 
regions of olive cultivation [4]. Alongside the major 
allergens Fra e 1 of the ash tree and Ole e 1 of the olive 
tree, there are a number of other allergens character-
ized for ash and olive tree, respectively. However, in 
contrast to recombinant olive components, none of the 
recombinant ash components are available for commer-
cial testing in the UniCAP-FEIA (fluorescence enzyme 
immunoassay) system.
The major allergen Fra e 1 shows high cross-reactivity 
with the major allergen Ole e 1. Both major allergens are 
glycoproteins and share high sequential similarity [2, 6]. 
Therefore, Ole e 1 is considered a potent marker to diag-
nose sensitization to ash pollen [7, 8]. Next to Ole e 1, 
Ole e 7 and Ole e 9 are commercially available for test-
ing in the UniCAP-FEIA system. Ole e 7 is a lipid trans-
fer protein [9] and its prevalence varies dramatically 
between geographical areas of high and low pollen expo-
sure [10–12]. Ole e 9 is a 1,3-ß-glucanase, the prevalence 
of this allergen is low, except in areas of extreme expo-
sure to olive trees [13, 14]. Both allergens are believed to 
be linked to higher prevalence of asthmatic symptoms 
[10, 11]. However, the presence of specific immunoglobu-
lin E (IgE) to ash or olive pollen and its components will 
strongly depend on the exposure to the allergen, which is 
varying within Europe and different regions.
In the European Union regulatory demands are rising 
for the production and use of any allergen solution used 
for diagnostic testing, favoring the use of “clean” compo-
nent resolved analysis [15]. The standard tools, such as 
extract based SPT (skin prick test) and serology to native 
extracts, contain many of the allergenic molecules within 
one test and therefore, are very cost effective. On the 
other hand, these test solutions contain different compo-
nents and partly at unknown concentrations, one reason 
for pushing component based diagnostic approaches.
Burbach et  al. state a clinical relevance for sensitiza-
tion to the Oleaceae family in Germany of about 50% 
[16]. Component based diagnostic tools might be useful 
to distinguish a clinically silent sensitized patient from an 
allergic patient. Several studies deal with this topic and 
point out that higher levels of specific IgE to e.g. Bet v 1, 
Der p 1 or Par j 2 could hint at a clinically relevant sensi-
tization to birch, house dust mite or parietaria, but clini-
cal relevance was not always proven by allergen challenge 
in these studies [17–19]. Especially in complex polysen-
sitized patients the reported period of allergic symp-
toms during the year can only give an indication towards 
the causing allergen and provocation testing usually 
is needed to clearly identify the allergen causing these 
symptoms besides various sensitizations.
Therefore, we questioned if it is useful to follow the 
trend of component based diagnostic approach on the 
basis of olive tree components Ole e 1, Ole e 7 and Ole 
e 9 for the diagnosis of ash sensitization or allergy in 
Germany.
Methods
Patient data
The Department of Oto-Rhino-Laryngology, Head & 
Neck Surgery of the Ludwig-Maximilians-University in 
Munich runs an allergy data base that contains all patient 
information and diagnostic results of patients who vis-
ited the allergy department. We retrospectively scanned 
this database for patients who presented to our depart-
ment between December 2009 and March 2017 and 
underwent nasal provocation testing (NPT) to ash pollen 
resulting in a total of 121 patients. We excluded patients 
who we could not clearly separate in ash allergic versus 
clinically silent sensitized, who did not receive SPT to ash 
at time of visit or if no serum was left for further analy-
sis. 113 patients were left and included in this study. All 
patients were positively tested to ash in SPT and partly 
had received serum diagnostic to ash/olive allergy. In all 
patients diagnostic for specific IgE to native ash extract 
and the allergen components rOle e 1, nOle e 7 and rOle 
e 9 were completed.
Nasal provocation test
In our study, beforehand all patients had received nasal 
provocation challenge with ash pollen to differentiate 
between allergy and sensitization without clinical rel-
evance. The NPT was performed in accordance with 
the current guidelines [20]. The intranasal challenge test 
solution for ash was designated for nasal provocation 
and had an allergen concentration of 5.000 BE/ml (Aller-
gopharma, Reinbek, Germany). Testing was considered 
positive if the intranasal airflow measured by rhinoma-
nometry was decreased > 40% at 150 Pa on the side tested 
with the allergen, as well as for a symptom score > 3 or 
a decrease in intranasal airflow > 20% in combination 
with a symptom score > 2; the symptoms registered were 
secretion (0 = no secretion, 1 = little secretion, 2 = plenty 
secretion), irritation (0 = 0–2 × sneezing, 1 = 3–5 × 
sneezing, 2 = > 5 × sneezing) and remote symptoms 
(0 = no remote symptoms, 1 = lacrimation and/or itching 
of palate and/or itching of ears, 2 = conjunctivitis and/or 
chemosis and or urticaria and/or coughing and/or dysp-
noe) [21].
Skin prick test
The SPT solution for ash pollen by ALK-Abelló, Wedel, 
Germany was used. The SPT was considered positive 
with a wheal > 3 mm in diameter (I = ≥ 3 to 4, II = ≥ 4 to 
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5, III = ≥ 5 to 6, IV = ≥ 6) in combination with Histamine 
dihydrochloride solution at 1  mg/ml as positive control 
and allergen-free saline solution as negative control. It 
was read 20  min after application. The procedure and 
classification were in line with European standards and 
published guidelines [22–26].
Fluorescence enzyme immunoassay (FEIA)
The FEIA method (UniCAP-FEIA, Thermo Fisher Sci-
entific, Freiburg, Germany) was used to detect IgE reac-
tivity to purified native ash allergen extract and allergen 
components rOle e 1, nOle e 7 and rOle e 9 with a com-
mercially available test kit (Thermo Fisher Scientific, 
Freiburg, Germany). All procedures were in accord-
ance with the manufacturer´s instructions. The results 
are given as ratio of specific IgE in concentration units 
(kU/l) and total IgE in concentration units (kU/l). The 
positive cutoff value was > 0.35 kU/l as suggested by the 
manufacturer.
Statistical analyses
Statistical analysis was performed on a Lenovo Think-
pad X61 s with SigmaPlot (Jandel Corp., San Rafael, CA, 
USA) and Excel (Microsoft, Redmond, WA, USA). The 
median was used for descriptive statistics since all data 
failed normality testing (Shapiro–Wilk). The Mann–
Whitney Rank Sum Test was utilized for testing statisti-
cally significant differences in the median values between 
the two groups. Correlation between native ash extract 
and rOle e 1 results was calculated by Spearman Rank 
Order Correlation with absolute values of specific IgE in 
kU/l. A p-value <0.05 was considered significant.
Results
In our study, a total of 113 patients had received NPT 
with ash pollen. Based on this we divided the patient col-
lective in 2 groups: ash pollen allergy and sensitization to 
ash without clinical relevance. 66 (58%) patients had an 
allergy to ash pollen, 47 (42%) patients showed a sensiti-
zation to ash without eliciting clinical symptoms. Table 1 
summarizes the patient data.
In terms of gender distribution, age, sensitization pro-
files and reported asthma both groups were comparable. 
We distinguished between patients mono-sensitized to 
ash, patients that were oligo-sensitized to 1–2 additional 
perennial or seasonal allergens, and patients poly-sen-
sitized to 3 or more allergens in addition to ash pollen. 
In summary, we looked at sensitizations to other trees, 
herbs, grass, animal dander, mold, mite and latex. Most 
patients, 94% of sensitized patients and 88% of allergic 
patients, were poly-sensitized. Also, 97 patients (86% of 
all patients) had a positive result in SPT with birch tree. 
In addition, an equivalent percentage of patients in the 
allergy and in the sensitization group reported asthma, 
45% of patients in the sensitization group and 49% in the 
allergy group. In terms of reported food allergy, we found 
a slightly higher percentage of patients in the allergy 
groups namely 41% compared to 28% in the sensitization 
group.
We compared different diagnostic tools within the 
allergy and sensitization groups (Table  2). All patients 
had a positive SPT for ash pollen. The median values of 
the SPT for ash pollen were III (range II–IV) in the sen-
sitization group and IV (range I–IV) in the allergy group. 
However, this difference was not statistically significant 
(p = 0.714). In terms of sensitization profiles of aller-
gic and asymptomatic patients we compared native ash 
extract and the olive tree components rOle e 1, nOle e 
7 and rOle e 9, as representative components of the 
Oleaceae family.
Prevalence of a specific IgE to native ash extract was 
99% in the allergy group and 98% in the sensitization 
group. Results are shown as ratio to total IgE, median val-
ues were 0.012 and 0.015, respectively. The two patients 
who were negative for the native extract according to 
the manufacturer´s suggested positive cutoff value of 
> 0.35 kU/l, in fact showed values of specific IgE to native 
extract of 0.2 and 0.25 kU/l. Both had a positive SPT (II 
and IV) and both showed low values for specific IgE to 
rOle e 1 (0.18 and 0.2 kU/l). Antibodies to the major 
allergen rOle e 1 were present in 88% of patients in the 
Table 1 Demographics and  characteristics of  patients 
with ash NPT
Values are number of patients total and percent of each evaluated group
Age is given as a median
Silent sensitization 
(n = 47/42%)
Allergy 
(n = 66/58%)
Male 34 (72%) 40 (61%)
Female 13 (28%) 26 (39%)
Age (range 5–76 years) 33.4 32.7
Mono‑sensitized 1 (2%) 2 (3%)
Oligo‑sensitized 2 (4%) 6 (9%)
Poly‑sensitized 44 (94%) 58 (88%)
Co‑sensitization to
 Other trees 45 (96%) 58 (88%)
 Herbs 21 (45%) 28 (42%)
 Grass 30 (64%) 42 (64%)
 Animals 30 (64%) 38 (56%)
 Mold 11 (23%) 16 (24%)
 Mite 23 (49%) 35 (53%)
 Latex 2 (4%) 1 (2%)
Asthma 21 (45%) 32 (49%)
Food allergy 13 (28%) 27 (41%)
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allergy group and in 87% of patients in the sensitization 
group. The median value of antibodies to rOle e 1 in rela-
tion to total IgE was 0.007 in the allergy group and 0.010 
in the sensitization group. Median values of antibodies to 
native ash extract and rOle e 1 did not differ significantly 
between both groups (p = 0.176 for native ash extract and 
p = 0.197 for rOle e 1). However, specific IgE to native ash 
extract and rOle e 1 highly correlated with a correlation 
coefficient of 0.83 (Spearman correlation p = 0.0000002) 
(Fig. 1). Prevalences of nOle e 7 and rOle e 9 were very 
low in both groups. In the allergy group only two patients 
had specific antibodies to the allergens nOle e 7 (3%) and 
two patients to rOle e 9 (3%), in the sensitization group it 
was only one patient with nOle e 7 (1%), no patient had 
specific IgE to rOle e 9. Patients having specific antibod-
ies to nOle e 7 or rOle e 9 also had specific IgE to native 
ash extract and rOle e 1. All of these 5 patients reported 
asthma, but only two reported a food related allergy.
Discussion
This study investigated native ash extract-based diagnos-
tic approaches and the use of component based diagnos-
tic tools in patients sensitized to European ash pollen in 
routine clinical practice in Germany, since ash and olive 
tree belong to the Oleaceae family and cross-reactivity 
between the two has been widely seen.
Our study collective does not represent the main 
population. The majority of patients are poly-sensitized 
indifferent of the existence of symptoms. This is due to 
the inclusion criterium of nasal provocation with ash 
pollen to clearly separate between clinically silent sensi-
tizations and allergy. Especially complex poly-sensitized 
patients are in need of provocation testing to relate 
symptoms to a specific sensitization. In mono- or oligo-
sensitized patients, the reported time of the year, the 
patient is suffering from symptoms, usually is in line with 
an individual sensitization. Therefore, mono-sensitized 
and oligo-sensitized patients are most likely underrep-
resented in this study, which leads to certain limitations 
that will be mentioned in the course of the discussion. 
On the other hand, especially complex poly-sensitized 
patients should benefit from component based diagnostic 
approaches.
Allergy to ash is frequently underestimated in Ger-
many [2]. An elaborate diagnostic approach is required 
to conclude possible therapeutic strategies in patients 
with clinical symptoms during March until May since 
ash and birch tree strongly overlap in their pollination 
period. In our patient collective 86% also had a positive 
SPT with birch. Testing ash sensitization via specific IgE 
to native extract is almost as effective as SPT to ash, 98% 
of our patients showed specific IgE. On the other hand, 
we would have missed two patients having levels below 
the positive cutoff value by testing specific IgE to native 
ash extract alone. Component based diagnostic of sen-
sitization to ash via testing for specific IgE to Ole e 1 is 
described as comparably effective in the literature [7], 
which could not be seen in our study. The above men-
tioned two patients without IgE to native extract also 
showed low levels of specific IgE to Ole e 1 below the 
positive cutoff value. Furthermore, twelve additional 
patients did not have specific IgE to Ole e 1 above the 
positive cutoff value of > 0.35 kU/l and would have been 
Table 2 SPT and sensitization profile to native ash extract 
and different olive components
SPT results are given as median and range
Values of serum diagnostic approaches are number of patients in total and 
percent of each evaluated group
IgE level ratios are given as median (range is shown as total values in kU/l)
Silent 
sensitization 
(n = 47/42%)
Allergy 
(n = 66/58%)
p-value
SPT III (II–IV) IV (I–IV) 0.714
Native ash positive 46 (98%) 65 (99%)
IgE level/total IgE 
level
0.015 (0.2–60.1) 0.012 (0.25–100) 0.176
rOle e 1 positive 41 (87%) 58 (88%)
IgE level/total IgE 
level
0.010 (0–66.3) 0.007 (0–100) 0.197
nOle e 7 positive 1 (2%) 2 (3%)
IgE level/total IgE 
level
< 0.001 (0–0.75) < 0.001 (0–0.77) No p
rOle e 9 positive 0 (0%) 2 (3%)
IgE level/total IgE 
level
< 0.001 (0–0.32) < 0.001 (0–2.14) No p
Fig. 1 Spearman Correlation of specific IgE to rOle e 1 and to native 
ash extract (n = 113). Levels of specific IgE to rOle e 1 and to native 
ash extract highly correlate with a correlation coefficient of 0.83 
(p =0.0000002)
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overlooked with an exclusive component based diag-
nostic approach. 9 of these 14 missed sensitizations 
were clinically relevant. Concluding, based on our study 
results native extract approaches such as SPT and spe-
cific IgE to native extract remain crucial in the diagno-
sis of sensitization and allergy in routine clinical practice 
and cannot been replaced by component based diagnos-
tic testing via rOle e 1 alone.
Presence of antibodies to nOle e 7 and rOle e 9 was rare 
in our patient collective. Only 5 patients in total showed 
positive values to one of these components. It is known 
that the prevalence of olive components depends on geo-
graphical location [27]. Sensitization to nOle e 7 and rOle 
e 9 strongly depends on the intensity of exposure to olive 
pollen [12–14]. Therefore, sensitization via ash pollen did 
not result in a specific immune response that could be 
detected by nOle e 7 and rOle e 9 serology in our study 
collective. Concluding, these components are not suit-
able for general diagnosis of sensitization and allergy to 
the ash tree in Germany, but of course may be crucial in 
other European countries, when sensitization occurs via 
olive tree.
It is reported for sensitization to e.g. cat that a high 
value in SPT and native extract serology can indicate the 
presence of an allergy versus a clinically silent sensitiza-
tion showing lower values [28]. This could not be seen 
for ash allergy and/or sensitization. Differences in SPT 
and serology of native ash extract or rOle e 1 were not 
statistically significant for both groups. Nevertheless, 
this might be due to the patient collective as mentioned 
above. Mono- and oligo-sensitized patients are under-
represented which could alter the results accordingly. 
Therefore, in complex poly-sensitized patients, NPT with 
ash pollen remains crucial in the diagnosis of a manifest 
allergy.
Sensitization to nOle e 7 and rOle e 9 is documented 
to be associated with asthma [10, 14]. Indeed, all patients 
with specific antibodies to the one or other allergen 
reported asthma. On the other hand, all nOle e 7 or rOle 
e 9 sensitized patients were poly-sensitized and in total 
53 patients (47% of all patients) reported asthma in this 
study. Both groups, patients only sensitized and patients 
allergic to ash, show an equal percentage of polysensitiza-
tion as well as asthma. Following, the majority of patients 
reporting asthma did not show any sensitization to nOle 
e 7 or rOle e 9. Therefore, we conclude that asthma in 
these patients is not a specific nOle e 7 or rOle e 9 effect.
Also, it was shown, that the presence of specific 
IgE to Ole e 7 is associated with higher risk for food 
induced anaphylaxis [14, 29]. Only 3 patients in our 
study had specific IgE to Ole e 7 and only one of them 
reported oral symptoms after the consumption of cer-
tain fruit but no severe anaphylactic reaction. Ole e 9 is 
presumed to be involved in the pollen-Latex-fruit-syn-
drome [14, 30]. Two patients in our study had specific 
IgE to Ole e 9, but none of them had a positive SPT for 
Latex or reported symptoms associated with the pol-
len-Latex-fruit-syndrome. However, the low prevalence 
of Ole e 7 and Ole e 9 in our study should not lead to 
any conclusion regarding food related symptoms.
In conclusion, this study provides evidence that test-
ing for the olive components rOle e 1, nOle e 7 and rOle 
e 9 alone is not sufficient to reliably identify ash sensi-
tized and ash allergic patients. In routine clinical prac-
tice diagnosing an allergy to European ash in Germany 
should be based on extract-based methods, such as the 
SPT and serology to native ash extract. Replacing these 
standard tools by only recombinant diagnostic with 
rOle e 1 or other olive allergen components could miss 
sensitized patients. Moreover, differentiation between 
manifest allergy to ash and clinically silent sensitization 
can only be reliably performed via NPT at least in poly-
sensitized patients. In routine clinical practice in Ger-
many, determination of serology for the commercially 
available olive components nOle e 7 and rOle e 9 does 
not seem to deliver any additional benefit in the diag-
nosis of ash allergy.
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